CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 15 enrolled
Drug / intervention
[18F]Fluorothymidine (FLT) PET/CT Imagingradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02108457
NCT02108457N/ACompleted
CompareCT.gov

[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers

Abramson Cancer Center at Penn Medicine·observational·Posted Apr 9, 2014·Updated Mar 30, 2021

In Brief

An observational study evaluating [18F]Fluorothymidine (FLT) PET/CT Imaging for Gynecologic Cancer. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the effect of specific bone marrow maps developed with18F-FLT PET/CT imaging on the ability to spare proliferating bone marrow using proton beam radiotherapy compared to IMRT. Participants will be 18 years of age or old with a history of gynecologic cancer. Subjects will undergo 3 FLT-PET scans (one before treatment, one during the course of RT, and one 2-5 weeks after initiation of RT). Scans will take place in the Department of Radiation Oncology.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGynecologic Cancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 9, 2014
Enrollment StartFeb 1, 2014
Primary CompletionDec 21, 2016
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 12.2 years ago

Interventions

[18F]Fluorothymidine (FLT) PET/CT Imagingradiation